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SUMMARY
Central retinal artery occlusion (CRAO) is an 
ophthalmological emergency. Various treatment 
modalities have been tried, but none have shown 
to alter natural history of the disease. Hyperoxia can 
restore retinal oxygenation, and favourable results 
were obtained with hyperbaric oxygen therapy (HBOT). 
We report two patients with sudden visual loss due to 
CRAO treated with HBOT. Case 1: a 61-year-old female, 
presented with CRAO in her left eye(OS). She was 
submitted to eight sessions of HBOT(2.4atmosphere 
absolute (ATA)). BCVA(Best corrected visual acuity) 
improved from counting fingers (CF) to 1.0 and 
fluorescein angiography (FA) showed a normalisation. 
Vascular study showed a value of 8.8% for HbA1c 
and ventricular extrasystoles. Case 2: a 69-year-old 
male presented with CRAO in his OS. Nine sessions of 
HBOT(2.4 ATA) were performed. Best corrected visual 
acuity (BCVA) improved from CF to 0.8 and the FA was 
normalised. Vascular study revealed an atheromatous 
carotid disease, and cardiac pathology. HBOT seems to 
be beneficial on the recovery of vision following CRAO.
BAckgRoUnd
Central retinal artery occlusion (CRAO) is an 
ophthalmological emergency and it is analogous to 
an acute stroke of the eye. The incidence is 1 in 
100 000 people.1 It is characterised by a sudden, 
unilateral and painless loss of vision. Embolism is 
the most common cause of CRAO, the major source 
of which being carotid artery disease.
The natural history of CRAO is the reperfusion 
of the artery over a few days. Meaningful improve-
ment (15 ETDRS (Early Treatment Diabetic Reti-
nopathy Study) letters or three lines in Snellen 
chart) occurs only in 10% of the patients with spon-
taneous reperfusion.
The prognosis is dependent on the particular 
vessel occluded, the location and degree of occlu-
sion, the presence or absence of cilioretinal arteries, 
the time interval until therapy and presence of alter-
nate sources of oxygen to ocular tissues.1
Traditional therapeutic regimens, including 
ocular massage, anterior chamber paracentesis, 
intraocular pressure-lowering medications, vasodi-
lators and oral diuretics, have shown to be unsuc-
cessful in the great majority of cases. Trombolytic 
agents and surgical embolectomy are associated 
with high haemorrhagic risk.1–3
Hyperbaric oxygen therapy (HBOT) has been 
associated with visual improvement in retrospective 
studies.2 HBOT can maintain oxygenation of the 
retina through the choroidal blood supply, decrease 
oedema and preserve compromised tissue adjacent 
to ischaemic area.2 4
We present two patients with CRAO who were 
submitted to HBOT. It is important to recognise 
that this treatment could be a good option if it is 
started earlier.
cASe pReSentAtion
Case 1: a 61-year-old woman patient presented 
to the emergency room with sudden loss of vision 
in the left eye (OS), which started 4 hours before 
the admission. Her past medical history included 
hypertension and type 2 diabetes mellitus. Her 
BCVA(Best corrected visual acuity) was CF OS and 
1.0 OD(right eye), on a decimal scale. A relative 
afferent pupillary defect (RAPD) was present OS. 
Biomicroscopy of both eyes was normal. Intra-
ocular pressure was normal in both eyes. Dilated 
fundus examination of the left eye showed an area 
of retinal whitening with redness in the foveal 
area. The right eye was normal. Spectral Domain 
Optical coherence tomography (SD-OCT) revealed 
increase in thickness and reflectivity of the inner 
retinal layers, consistent with intracellular oedema 
(figure 1A). Fluorescein angiography (FA) showed 
a delay on the filling phase of the central retinal 
artery (figure 2).
Case 2: a 69-year-old Caucasian man presented 
to the emergency room with sudden loss of vision 
in the left eye, started 2.5 hours before admission. 
Past medical history was significant for arterial 
hypertension and type 2 diabetes mellitus. BCVA 
was CF with positive RAPD OD and 1.0 OD. The 
anterior segment examination, intraocular pressure 
and fundus examination were normal in both eyes. 
FA of the left eye demonstrated delayed filling of 
the central retinal artery. OCT showed increase in 
thickness and reflectivity of the inner retinal layers, 
consistent with intracellular oedema.
tReAtMent
Case 1: the patient was referred to the Hyperbaric 
Medical Unit of Hospital Pedro Hispano, and was 
submitted to the first session of hyperbaric treat-
ment at 2.4 ATA (atmosphere absolute) oxygen 
(100%), during 90 min, in a gas chamber. The first 
session was done 6 hours after the onset of symp-
toms. She was submitted to two additional daily 
sessions of 90 min, on each one of the next 3 days, 
and one additional session on the fifth day.
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Case 2: ocular massage was performed and topical antihy-
pertensive medication was prescribed. Immediate referral to 
the HBO centre was undertaken. The first HBOT session was 
preformed 4 hours after the onset of the symptoms, in a gas 
chamber of the Hyperbaric Medical Unit of Hospital Pedro 
Hispano, at 2.4 ATA oxygen (100%). Two additional daily 
sessions (90 min) were prescribed in the next 2 days, followed by 
only one daily session for the next 5 days.
oUtcoMe And follow-Up
Case 1: patient was checked for any other disease which could 
cause vascular occlusion, and we found a value of 8.8% for 
HbA1c in laboratory tests, and the presence of ventricular extra-
systoles on Holter (figure 3).
Three days after starting HBOT, BCVA OS improved to 1.0. 
Seven weeks after the initial visit, FA was repeated and showed 
normal fluorescein filling of the central retinal artery (figure 4). 
OCT was done in each one of the 3 days after the diagnosis, 
and was repeated after the 9th and 37th days (figure 1B). The 
thickness of the inner retina started to reduce on the third day 
after the diagnosis, and stabilised since the ninth day.
Case 2: patient was checked for any other disease which 
could cause vascular occlusion, laboratory examination showed 
hyperglycaemia and hyperkalaemia. The carotid echo-Doppler 
demonstrated atheromatous carotid disease, without significant 
dynamic repercussion, and echochardiogram found an enlarge-
ment of left auricle and hypertrophy of left ventricle, with mild 
aortic insufficiency.
Thirteen days after the initiation of therapy, the visual acuity 
of the left eye improved to 0.8.
Ten days after the initial visit, control FA showed improvement 
in fluorescein filling of the central retinal artery (time arm-retina, 
23 s). OCT was done in each one of the 3 days after the symp-
toms, 1 and 2 months after. The thickness of inner retina started 
to reduce in the 10th day and stabilised on the 14th day.
diScUSSion
HBOT is a treatment modality that can be used in many ocular 
pathologies. With hyperbaric oxygenation, oxygen can reach 
both inner and outer retinal layers retina by the choroid. An 
early administration of HBOT is extremely necessary to prevent 
irreversible damage to the retina.1–4
The administration of supplemental oxygen in the treatment 
of CRAO must be continued until flow through the retinal artery 
has resumed to a level sufficient to maintain inner retinal viability 
under normoxic conditions.1 Ideally, the shorter the time delay 
until treatment, the better the likelihood of recovering ischaemic 
retina that is threatened but viable.1
In the clinical setting of CRAO, however, some residual retinal 
blood flow has been detected by angiography. This may help 
explain the variability in visual outcome with different time 
delays until treatment.
Literature suggests that HBOT can also reduce macular 
oedema.5 The thickness of the inner retinal layers of our patients 
showed a progressive reduction, comparing with their fellow 
eyes, consistent with the reduction of the oedema.
figure 1 The first Spectral Domain Optical Coherence 
Tomography (SD-OCT) (A) revealed an increase in thickness and 
reflectivity of the inner retinal layers. The outer retinal layers are 
normal. The SD-OCT (B) performed 9 days after the diagnosis showed a 
normalisation of the inner retinal thickness.
figure 2 The first fluorescein angiography showed a non-perfusion 
(delay for more than 3 min) of the central retinal artery, with near 
normal choroidal perfusion.
figure 3 Twenty-hour Holter showed ventricular extrasystoles with 
ultrashort coupling interval (260 ms) and a non-sustained polymorphic 
ventricular tachycardia initiated by extrasystoles with short coupling 
interval.
figure 4 The second fluorescein angiography (after 7 weeks) revealed 
a normal fluorescein filling of the central retinal artery arterioles and 
capillaries, started at 18 s. There is no retinal or macular ischaemia.
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Based on American Heart Association classification of 
evidence, treatment of CRAO with hyperbaric oxygen treatment 
is level IIb. There is fair to good evidence to support its use. It 
is acceptable and safe, but lacks confirmation by level I studies. 
There are no alternative therapies with similar outcomes.1
Many studies have reported that HBOT is useful in the treat-
ment of CRAO,5–12 but that are different opinions about the 
period of time when HBOT can be useful. Butler et al11 reported 
that the best evidence is a delay of <12 hours. Hertzog et al12 
and Beiran et al8 described that HBOT is most useful when 
started within 8 hours of onset visual loss.
The Undersea and Hyperbaric Medical Society advises that 
HBOT should be started in the first 24 hours after the onset of 
the symptoms, and it is reported that results are better if it is 
done in the first 12 hours.13
Some authors describe that there are four important key 
factors to determine the HBOT success: time at HBOT is started, 
degree of vessel occlusion, the type of vessel that is occluded and 
the presence of an adequate PaO2 of oxygen. The aetiology of 
the occlusion is also related as an important factor.1 4 6 14
The major barrier to effective treatment for CRAO is the fact 
that people are rarely seen acutely and there is no consensus for 
treatment or guideline-based therapy.4
Our patients responded to the HBOT treatment well. The 
improvement may be related to the early timing of the treatment 
of our patients (6 hours) and the absence of other ophthalmolog-
ical problem or precipitating factor.
learning points
 ► Hyperbaric oxygen therapy (HBOT) seems to be an option for 
the treatment of central retinal artery occlusion (CRAO) that 
can be easily administrated.
 ► HBOT produce an improvement in vision if it is done in the 
first 24 hours after the onset of the symptoms.
 ► Further studies with more patients are necessary to 
determine the value and safety of this therapy in the 
treatment of CRAO, as well as the exact time window to 
perform HBOT.
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